App-Quantinova.ai

Safety and emerging evidence of immune modulation of the live biotherapeutic MRx0518 in the neoadjuvant setting for patients awaiting surgical removal of solid tumours

Mark Lythgoe - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Releasing the restraints of Vγ9Vδ2 T-cells in cancer immunotherapy

Laura Ridgley - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Zoledronic acid

Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC)

Rahul Aggarwal - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Metastatic castration-resistant prostate cancer

Pembrolizumab

Safety and efficacy signals in the complete phase I study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors (ICIs)

Shubham Pant - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

Targeting the apical intracellular checkpoint CISH unleashes T cell neoantigen reactivity and effector program

Douglas Palmer - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients refractory to immune checkpoint inhibitors

Shubham Pant - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Bladder Cancer

Pembrolizumab

IL-2 augments immTAC-dependent T cell activation and tumour cell killing

Duncan Gascoyne - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Renal cell carcinoma

Aldesleukin

Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors

Fabrice Barlesi - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Atezolizumab

A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers

Patrick van Berkel - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Interleukin

A phase II study (TACTI-002) of eftilagimod alpha (a soluble LAG-3 protein) with pembrolizumab in PD-L1 unselected patients with metastatic non-small cell lung(NSCLC) or head and neck carcinoma(HNSCC)

Matthew Krebs - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

EDP 202

SARS-CoV-2 specific T-cells in TIL from patients with epithelial cancer

Pedro Noronha - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

IL-15

Long-term clinical outcomes associated with sequential treatment of BRAF mutant advanced melanoma patients

Ahmad Tarhini - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

N/A

Early results from a phase 1 study to evaluate safety, pharmacokinetics, and efficacy of AMG 404, a programmed death-1 (PD-1) antibody, in patients with advanced solid tumors

Timothy Price - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

AGEN2373 is a CD137 agonist antibody designed to leverage optimal CD137 and FcγR co-targeting to promote antitumor immunologic effects

Claire Galand - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

N/A

Urelumab

Generalizability of potential biomarkers of response to CTLA-4 and PD-1 blockade therapy in cancer

Dante Bortone - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Interferon

AMG 757, a half-life extended bispecific T-cell engager (BiTE®) immune therapy against DLL3 in SCLC: phase 1 interim results

Hossein Borghaei - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Small cell lung cancer

N/A

Pembrolizumab plus lenvatinib vs chemotherapy and lenvatinib monotherapy for recurrent/metastatic head and neck squamous cell carcinoma that progressed on platinum therapy and immunotherapy: LEAP-009

Kevin Harrington - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Squamous cell carcinoma of the head and neck

Pembrolizumab

C-reactive protein (CRP) as a prognostic biomarker in advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Results from a multi-center international observational study

Abdul Rafeh Naqash - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Interleukin

Association of response with survival outcomes with atezolizumab in combination with vemurafenib and cobimetinib in the phase 3 IMspire150 study

Paolo Ascierto - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Melanoma

Atezolizumab

A first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1, in patients with advanced cancer and resistance to PD-(L)1 therapy

Timothy Yap - International Society for Biological Therapy of Cancer (SITC) , 2020

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

FS118

Filters

45280 Abstracts